allegro industries

Pall Corporation Secures Multi-Million Dollar Contract With Exothera

– Pall Corporation, a global leader in filtration, separation and purification, today announced a new contract worth more than $7M with full-service contract development and manufacturing organization (CDMO) Exothera S.A.

Pall Corporation (PRNewsfoto/Pall Corporation)

The new contract with Pall will establish a suspension-based manufacturing platform of up to 2000L, using a range of technologies including Allegro STR single-use bioreactors. The new installation allows for the production of a variety of viral vectors for gene therapies and viral vector-based vaccines.

Exothera recently announced a significant expansion of its manufacturing capabilities, with two new state-of-the-art Good Manufacturing Practice (GMP) facilities built at the company’s Jumet site near Brussels, Belgium . The new facilities, which are roughly 92,000 square feet and include a variety of functions from research and development to commercial production, will begin GMP production this summer.

Clive Glover , General Manager, Gene Therapy at Pall Corporation, said: “There is a strong pipeline of viral vector-based gene therapies and vaccines and the importance of rapidly realizing industrial-scale production for these vaccines and therapies has been brought into sharp focus by COVID-19. Pall has considerable process development expertise from working with many of the industry leaders to develop scalable upstream and downstream processes. We’re thrilled to bring this experience to support Exothera as they expand their manufacturing capabilities.”

The gene therapy and vaccine industries are facing complex challenges when scaling up vector-based processes. According to Vasily Medvedev , head of development at Exothera, the company selected the Pall end-to-end solution based on its flexibility and its capability to scale up processes quickly and efficiently.

“We selected Pall for their technological excellence and strong track record in the gene therapy and vaccines industries, as well as the level of support the team provides,” explained Medvedev. “They offer a robust and cost-effective single-use solution.”

Christian Borgniet, Chief Operating Officer of Exothera, added: “Compared to other suspension solutions, Pall’s STR bioreactors are well-suited and could be adapted, if needed, to the perfusion mode, allowing higher growth and density of cells. We are pleased to establish this partnership with a very supportive company that is willing to transfer its expertise.”

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit https://www.pall.com .

Or follow us on social media:

LinkedIn   Twitter Facebook

Corporate Media Contact:  
Pall Corporation
Amanda Comeau
Director, Corporate Communications
(508) 330-0811

About Exothera SA
Exothera is a viral vector CDMO (contract manufacturing and development organization) leveraging standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing.

LinkedIn : https://www.linkedin.com/company/exothera / Website : www.exothera.world

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/pall-corporation-secures-multi-million-dollar-contract-with-exothera-301323764.html

SOURCE Pall Corporation

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
  Loyal Lithium Limited

Strategic Consolidation of Hidden Lake and Board Changes

Loyal Lithium Limited (ASX:LLI) (Loyal Lithium, LLI, or the Company) is pleased to announce the execution of a definitive agreement for the consolidation of the Hidden Lake Lithium Project, with Patriot Battery Metals (ASX:PMT) becoming a substantial LLI shareholder. Mr. Blair Way, Non- Executive Director and former President & CEO of Patriot Battery Metals, will join the Loyal Lithium Board of Directors, bringing valuable regional and industry expertise to guide the company's growth initiatives. The consolidation of the Hidden Lake Lithium Project provides Loyal Lithium with greater flexibility and optionality to deploy innovative exploration and development solutions.

Keep reading...Show less
Drilling Commences at the Barra Lithium Project in Brazil

Drilling Commences at the Barra Lithium Project in Brazil

Summit Minerals Limited (ASX:SUM) (“Summit” or the “Company”) is pleased to announce that Summit’s maiden drilling program has commenced at the recently acquired 100% owned Barra Lithium Project (“Barra”).

The Barra Lithium Project consists of four recently acquired tenements that are located within close proximity to the existing operating Miranda Lithium mine that is within the Borborema Pegmatitic Province (“BPP”) in northeast Brazil.

Keep reading...Show less
Lithium Universe

Lithium Universe


Keep reading...Show less
CleanTech Lithium (AIM:CTL)

Issue of Equity and TVR


Keep reading...Show less

Latest Press Releases

Related News

×